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Background: Hematological and biochemical abnormalities are among the most common clinicopathological
manifestations of HIV patients on ART. Consequently, the development and assessment of indigenous antiretroviral
drugs with minimal abnormalities becomes a necessity. The objective of this investigation was to assess potential
haematological and biochemical abnormalities that may be associated with the administration of Winniecure ART
in HIV patients undergoing treatment in Nigeria. Fifty (50) confirmed HIV positive ART naïve patients aged 36 ± 10
were observed for haematological and biochemical responses for 12 weeks. Haematological responses were
assessed thrice at 6 weeks interval using coulter Ac-T differential analyser and biochemical indicators (bilirubin,
creatine, urea, amylase, ALT, ALP, AST, albumin) assayed spectrophotometrically.
Results: The biochemical parameters ALP (P < 0.05), ALT (P < 0.0001), AST (P < 0.001) and amylase (P < 0.05) slightly
increased at the 12th week, no significant change was observed in plasma creatinine and urea concentrations while
albumin levels decreased non-significantly (P > 0.002). Haematological results showed consistent reduction of ESR,
eosinophil, absolute and differential lymphocytes, granulocytes and total WBC in the test subjects throughout the
assessment period. Conversely, haemoglobin, platelet and PCV increased significantly (P < 0.05). At the 12th week
thrombocytopenia (10.30%) and anaemia (76%) were reduced to 2% and 31% respectively while neutropenia (4.2 to 8%),
leucopenia (26.8 to 30%) and lymphopenia (1 to 10%) increased. No cases of neutrophilia, lymphocytosis, eosinophilia
and leukocytosis was observed.
Conclusion: The drug has a reduced haematological abnormalities and normal kidney function was unaffected though
there were signs of possible abnormal levels of hepatic enzymes beyond 12 weeks of treatment.
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The human immunodeficiency virus (HIV) is one of the
most important emerging infections of this century. It is
probably one of the diseases with multiple impacts on
persons, families, communities and the entire society. HIV
is threatening especially in sub-Saharan African countries.
In Nigeria for instance the prevalence rose from 3.8% in
1993 to 5.8% in 2001 [1]. Since the discovery and isolation
of HIV in 1983, there has been significant progress in un-
derstanding the viral pathogenic proteins that cause the
acquired immunodeficiency syndrome (AIDS) [2]. The* Correspondence: barthokeyibeh@yahoo.com
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reproduction in any medium, provided the orsubsequent development of HIV detection and quantifica-
tion techniques is now used extensively both in research
and routine clinical screening [3-6]. These techniques
have provided a more complex understanding of the epi-
genetics, epidemiology and clinical features of the infec-
tion [7,8].
It is observed that the emergence of drug development
programmes by government agencies, research establish-
ments and pharmaceutical industries has led to many
potent anti-HIV drugs called antiretrovirals [9]. Pres-
ently, a combination of these drugs known as highly ac-
tive antiretroviral therapy (HAART) is recommended as
a standard medication for the management of HIV in-
fection. The advent of HAART, a cocktail of nucleoside
and non-nucleoside analogues with potential to inhibitd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a reduced progression of the HIV infection to AIDS
[11]. This however, results in improved quality of life of
people living with HIV/AIDS [12].
It is undoubtedly observed that the HIV drugs are
without some adverse medical effects with implicit safety
limitations. Certain documented side effects of these
drugs include diarrhea, nausea, abnormal distribution of
body fats, anemia, neutropenia and cytopenia [13]. The
need to consider the safety of any novel antiretroviral
drug is of great importance and in line with centre for
disease control and prevention (CDC) standpoint which
advocated for evaluation of ART safety before being
considered for administration. The present work there-
fore evaluates independently, possible hematological
and biochemical abnormalities that maybe associated
with Winniecure antiretroviral drug.
It is highly documented that the hematological conse-
quences of HIV infection is dominated by peripheral
blood cytopenia. This has become more common with
the advent of antiretroviral therapy and related treat-
ments for HIV-associated infections and malignancies
[14,15]. Generally, in patients undergoing ART, anaemia
may occur in approximately 60-70%, neutropenia in 50%
and thrombocytopenia in 40% [16]. It is common that
the incidence and severity of low cell count increases
with advancing HIV disease. An exception to this is
thrombocytopenia which maybe an early manifestation
of HIV infection occurring in 3 to 12% of asymptomatic
patients [17,18]. In addition myelo suppressive therapies
and marno-infiltrating opportunistic diseases may fur-
ther contribute to the development of cytopenia similar
to the anaemia of HIV infection. An interesting clinical
significance observed in Zidovudine (ZDV) and some
drugs used for the treatment of opportunistic diseases is
that they may produce therapy with HIV-induced neu-
tropenia (a haematological abnormality) [19].
In view of the various questions raised by end users of
antiretroviral therapy such as the safety and efficacy of
the drug, a careful study of some possible abnormalities
that may be associated with Winniecure an antiretroviral
drug used in Nigeria was investigated.
Methods
Study population and ethics
Fifty confirmed HIV positive patients who were previ-
ously ART naive volunteered to take Winniecure anti-
retroviral therapy at a prescribed dose of 5 ml (1 tea
spoonful) containing 250 mg Winniecure extract taken 3
times daily for 5 days and then 2 times daily for the
period of this study (12 weeks). The study also had 100
HIV negative ART naive subjects attending clinic for the
first time and this served as the study reference subjects
or control group. All consenting subjects were recruitedconsecutively for the work. Blood samples were taken in
accordance with the Nigerian National Ethics and Oper-
ational Guidelines for Research on Human subjects
(NNEOGRHS). Part of the blood was collected into
EDTA container to give blood-anti-coagulant concentra-
tion of 2 mg/ml of blood with sterile syringe (aseptic
precautions were taken). The samples were collected at
intervals of 6 weeks for the whole period of this study. A
total of 150 subjects with an average age of 36 ± 10 for
HIV+ ART subjects and 40 ± 52 for the control group
were recruited for the study.
The inclusion criteria for enrolment of the study sub-
jects were specified as follows; subjects must be either
males or females aged 17 years and above, have con-
firmed laboratory evidence of HIV infection, accept to
abide by the prescribed dosage of the drug, have his-
tory of no previous antiretroviral therapy (ART naive)
and have CD4 cell counts between 50 and 350 cells/μl.
Exclusion criteria include those with recent blood
transfusion.
A structured questionnaire was filled by the subjects
in order to obtain demographic data and clinical history
and assistance was given on request. Prior to initiation
of treatment, the HIV serostatuses of the patients were
reconfirmed. Plasma samples from each of the patients
were tested using double rapid tests kits (Cappillus and
Unigold: Trinity BioTech, Ireland) and an ELISA
method (Genie II HIV-1 & 2 kit). The tests used have
different antigenic compositions.Haematological analysis
Parameters such as Hb, PVC, Total WBC, Differential
WBC, platelet count and ESR were evaluated each time
samples were collected from the subjects. Samples for
ESR were analyzed using Westergren method [20]. Blood
(2 ml) was diluted in 0.5 ml Trisodium Citrate solution
using the Westergren pipette that was filled to a zero
mark and mounted on a stand with the time adjusted to
exactly 1 hour for the red cell to sediment. The column
of the sedimented red cells was read at exactly 1 hour.
Results were reported in mm/hour. Other haemato-
logical parameters; Hb, PCV, total WBC, differential
WBC and platelet counts were analyzed with a haema-
tology analyzer (Beckman Coulter AcT Diff. Hemato-
logy Analyzer). A suspension of blood cells was passed
through a small orifice simultaneously with an electric
current which introduces an impedance change in the
orifice determined by the size of the cell. The system
counts the individual cells and provides cell size distri-
bution. The number of cells counted per sample is ap-
proximately 100 times greater than the usual microscope
count which reduces the statistical error by a factor of
approximately 10 times.
Table 1 The baseline characteristics of the study
population indicating CD4 count grouping, ART duration,




(n = 50) (n = 100)













1.50-200 cells/μl, 6, (12) 1100 ± 82 cells/μl
11.200-350 cells/μl 44, (88)
Comparison of data was done at P < 0.05, data on gender, marital status and
CD4 cell count (measured as cells/ μl) was presented as absolute numbers (n)
and percentages (%) while age was shown as mean ± standard deviation in
years. NA indicates none applicable. Data with different superscript indicates
statistical significance.
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Certain abnormalities were determined in the subjects on
antiretroviral treatment. Here anemia was defined as
haemoglobin <13 g/dl (men) and <12 g/dl (women) while
leucopenia as total WBC count less than 4000 cells/μl.
Total platelet count <150 × 103/μl was considered as
thrombocytopenia. However, neutropenia was judged as
absolute neutrophils/granulocytes count <1000 cells/μl
and lymphocytopenia considered at absolute lymphocyte
count of <800 cells/μl. Lymphocytosis, an increase in the
number of lymphocytes was considered when the absolute
lymphocyte count was greater than 4000 cells/μl. Neu-
trophilia indicates an elevated absolute granulocyte
count above 7000 cells/μl while leukocytosis is defined
as a total WBC more than two standard deviations
above the mean, i.e. a value of greater than 11,000 cells/μl
in adults. Also eosinophilia was evaluated at eosinophil
count above 450 cells/μl. Absolute CD4 cell count deter-
mination was done by flowcytometric analysis.
Biochemical analysis
Biochemical indicators were assessed at the first and last
visits only. Commercially available kits were used to assay
for the following serum enzymes: ALT, AST and amylase.
Urine creatine (RANDOX) and urea (BioVision) were also
determined using test kits. Bilirubin was measured directly
by use of bilirubin oxidase [21] while albumin concentra-
tion was obtained by BCG (Quantichrom™ BCG Albumin
Assay kit [DIAg-250] at 620 nm. This method is used daily
in clinical laboratory measurement in Nigeria and the re-
sults are comparable to those of electrophoresis. Manufac-
turer’s procedure for each test was followed accordingly.
Spectrophotometer was used to measure absorbance and
results calculated correspondingly. Normal ranges were
reported based on the results of the test kits used.
Statistical analysis
All data analysis was done using SPSS version 17 statis-
tical software package. Data was presented as Means ±
Standard deviation (SD) and calculations done using the
Student’s t-test and one-way ANOVA. Differences were
considered to be of statistical significance at an error
probability of less than 0.05 (P < 0.05).
Results
Study population
There was no significant difference between the ages of
the HIV+ HAART group (36 ± 10) and that of the refer-
ence group (40 ± 52). A non-significantly higher (P > 0.05;
52%) number of HIV+ females and a significant increase
(P < 0.05; 66%) in married couples amongst the HIV+ ART
group were observed. However, 88% of the HIV+ ART
subjects had CD4+ cells within the range of 200-350 cells/μl
while 12% were between 50-200 cells/μl (Table 1).Haematological analysis
Table 2 summarizes the mean ± SD of some haemato-
logical parameters of HIV+ ART patients on Winniecure
therapy before treatment (1st assessment) and subsequent
appointments at 6 weeks interval otherwise referred to as
visits in this study.
A comparative statistical analysis was made between
the 1st assessment visit and subsequent visits (treatment
period) (Table 2). A consistent reduction in ESR, eosino-
phil, total white blood cell (WBC), absolute & differen-
tial lymphocyte and absolute & differential granulocyte
of the patients from the 1st to the 3rd assessment visits
was observed with a lower value when compared to the
obtained reference values. An exception was noted on
ESR which significantly increased on comparison with
the reference values. Conversely, we noted a consistent
significant (P < 0.05) increase in haemoglobin, platelet
and packed cell volume from the 1st to the 3rd assess-
ment visits. All values obtained here was lower than the
reference value.Biochemical analysis
The concentration of these biochemical parameters;
ALP (EC 3.1.3.1; P < 0.05), ALT (EC 2.6.1.2; P < 0.0001),
AST (EC 2.6.1.1; P < 0.001), amylase (EC 3.2.1; P > 0.05)
and direct bilirubin was significantly increased (upper
range) at the third visit though still within the acceptable
normal range (Table 3). No remarkable change in plasma
creatinine and urea concentrations was observed when
Table 2 Haematological parameters of HIV patients on Winniecure ART from the 1st assessment visit (before treatment)
to the last visit ( 12th week)
Parameters 1st visit 2nd visit 3rd visit Reference value
ESR (mm/1 hr) 41.46 ± 31.01a 40.33 ± 35.36a 32.12 ± 15.49b 19.6 ± 40
Total WBC (×103 cells/μL ) 6.23 ± 1.96a 5.70 ± 0.06 b 5.65 ± 0.73b 8.40 ± 1.5
Absolute lymphocytes (×103 cells/μL ) 3.04 ± 1.44a 2.48 ± 0.68b 2.30 ± 0.51b 3.88 ± 2.5
Absolute granulocytes (×103 cells/μL ) 3.03 ± 1.46a 2.90 ± 0.64a 2.70 ± 0.72b 4.21 ± 1.5
Differential granulocytes (%) 51.54 ± 11.58a 49.50 ± 9.70b 48 ± 3.76b 57 ± 5.48
Haemoglobin (g/dl) 10.37 ± 1.15a 10.64 ± 1.55a 11.7 ± 1.01b 14 ± 0.9
Packed cell volume (%) 34.66 ± 5.56a 32.63 ± 5.14a 36.75 ± 1.53b 51 ± 3.23
Platelet (×103/μl) 211 ± 68.11a 305.9 ± 56.25b 310 ± 49.54b 320 ± 42
Differential lymphocytes (%) 61.26 ± 16.58a 45.50 ± 11.90b 49.00 ± 5.66b 59 ± 2.53
Eosinophil (μl) 197.01 ± 1.42a 177 ± 1.44b 132 ± 1.42c 242 ± 1.42
Comparison was made between the 1st visit and subsequent visits (treatment period) using ANOVA at a 5% level of significance. Reference values are values
obtained from the HIV negative healthy control group. Data with different superscript a,b and c indicates significant difference at P < 0.05.
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creased non-significantly (P > 0.002) when compared with
the reference value.
Abnormalities
Various haematological abnormalities maybe associated
with administration of antiretroviral drugs. The study re-
veals a higher incidence of thrombocytopenia (10.30%)
and anaemia (76%) in ART HIV+ subjects at the first
visit. Conversely, these decreased (thrombocytopenia-2%
and anaemia-31%) at 3rd assessment visit/12th week
(Figure 1). Neutropenia (4.2%), leucopenia (26.8) and
lymphopenia (1%) were low at the first visit but showed
higher values; 8%, 30% and 10% respectively at the 12th
week/3rd visit (Figure 1). No cases of neutrophilia, lym-
phocytosis, eosinophilia and leukocytosis was observed
or associated with the drug administration.
Discussion and conclusions
The study seeks to evaluate some haematological and
biochemical indicators of abnormalities in HIV infected
patients administered with Winniecure chemotherapeuticTable 3 Concentration of some biochemical parameters betw
undergoing ART
Parameters 1st visit 3r
AST (U/l) 31.66 ± 25.20a 34
ALT/(U/l) 21.38 ± 14.26a 38
ALP (U/l) 88.4 ± 21.31a 97
Amylase (U/l) 59.43 ± 42.62a 71
Plasma urea (mmol/l) 4.17 ± 8.22a 4.2
Plasma creatinine (mmol/l) 1.20 ± 0.99a 1.1
Direct bilirubin (mg/dl) 0.19 ± 0.10a 0.2
Albumin (U/l) 3.3 ± 2.3a 3.0
Data on 1st and 3rd visits were compared against the reference values using ANOVA
HIV negative healthy control group. Data with different superscript a,b and c indicateagent used in the treatment of HIV/AIDS in some parts
of Nigeria.
HIV infection has been reported to cause diverse de-
gree of immunopathogenesis in man [22] and this carries
enormous haematologic and biochemical consequences.
The haematologic implications of HIV infection is domi-
nated by peripheral blood cytopenias which, have be-
come more common with the advent of antiretroviral
(AR) therapy. Winniecure has been shown to inhibit
viral replication and could restore human immunity ne-
cessitating its use in the region as anti-HIV medication.
As an antiretroviral therapy, it could trigger haemato-
logic consequences as also seen in other AR drugs [23].
Winniecure is a herbal composition of Fiscus exaspirata,
Fiscus sur, Sida acuta/Sida corymbosa with a strong
hydrophilic nature, moisture content of 0.1% and density
1.936 ± 0.2. It has the following phytochemicals; tannins,
saponins and carbohydrates [24]. Previous studies have
reported its safety in humans and animals [25].
The baseline characteristics of the study population
showed no significant age difference between the refer-
ence or control group with that of the test subjects. Thiseen 1st visit (baseline) and 3rd visit in HIV+ subjects
d visit Reference value P-value
.31 ± 52.21b 25 ± 80c P < 0.001
.47 ± 22.66b 20 ± 12.2a P < 0.0001
.31 ± 29.1b 62 ± 11c P < 0.05
.21 ± 41.26b 80 ± 25.31b P > 0.05
1 ± 13.64a 4.3 ± 10a P < 0.002
0 ± 1.01a 1.23 ± 0.9a P < 0.629
1 ± 0.11b 0.18 ± 0.07a P < 0.001
2 ± 2.8a 4.2 ± 1.1b P < 0.002
at a 5% level of significance. Reference values are values obtained from the
s significant difference.
Figure 1 Distribution of haematologic abnormalities (Cytopenia) observed in HIV+ subjects taking Winniecure ART. This figure illustrates
the distribution of haematological abnormalities (Cytopenia in percentages %) observed in HIV+ subjects taking Winniecure ART. The bars
compares the abnormality at baseline (1st wk) and at the 12th wk of ART administration. Abnormalities presented include anaemia, neutropenia,
leucopenia, lymphopenia and thrombocytopenia.
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pharmacological effect of age on chemotherapeutic agent.
The number of HIV infected subjects are generally
reported to be higher in the female gender than in the
male counterpart [26]. The results obtained here
showed a higher number of female subjects on ART
when compared with the reference (HIV seronegative
subjects) group. HIV/AIDS has so far severely affected
more women than men in sub-Saharan Africa. Here fe-
males account for almost 57% of adults living with HIV/
AIDS. It is known that of all HIV infected youths in the
world (5.4 million), over three million are female [27].
This is so because the virus is more easily passed on to
young women owing to their immature vaginal tracts
and easily torn tissues. Also contributing to this increase
is gender inequalities in many tribes in African which,
prevent young women from negotiating safer sexual
practices that include use of contraceptives such as con-
dom. This influence may account for the increase in the
female prevalence rather than the sheer believe on
socio-cultural aspects of feminine disposition to attend-
ing HIV clinic.
It is generally believed that single/unmarried young in-
dividuals are more likely to acquire HIV infection than
married partners [28]. Contrarily, the study showed a
higher incidence of HIV infection in married partners
when compared to single/unmarried individuals, this
concurs with the report of other researchers [29,30].Inasmuch as unmarried/single individuals are likely to
engage in multiple sex partners, it is the authors opin-
ion that this group may likely have higher propensity to
use protection mechanism against HIV infection than
in married individuals with limited sexual partners.
Haque and Soonthorndhada [31] previously reported
increased STI risk perception and reason for condom
use in unmarried young individuals than their married
counterpart.
HIV patients assessing ART have been reported to
have an increased CD4 cell count, normally initiating
treatment from 100-260 cells/μl baseline [32,33]. Starting
ART at CD4 cell counts below 50 cells/μl increases the
relative risk of death by approximately 60% when com-
pared with ART initiation at 150-249 cells/ul CD4 [34].
Majority (88%) of the study subjects have CD4 cell count
between 200-350 cell/ul (i.e. category II based on CDC
classification). This shows that the immune status of the
subjects fall within the recommended CD4 count for ART
initiation (Table 1).
In the course of ART administration, clinically signifi-
cant haematologic abnormalities maybe common in per-
sons with HIV infection. Impaired haematopoiesis,
immune-mediated cytopenias and altered coagulation
mechanisms have all been described in HIV-infected in-
dividuals. Abnormalities may occur in individuals as a
result of the following actions; HIV infection, sequel of
HIV-related opportunistic infections, malignancies and
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sociated conditions. In the study findings a significant
variation was observed in some of the haematological
parameters examined in HIV+ subjects on Winniecure
treatment (Table 2). The following haematological abnor-
malities (Figure 1) were thus observed; thrombocytopenia,
anaemia, neutropenia, leucopenia and lymphopenia.
Generally, the overall White Blood Cell (WBC) count
is important to monitor because elevation of WBC may
indicate infection, lack of response to treatment or an
abnormality. The total WBC count shows a consistent
significant reduction in all the visits although the reduc-
tion at the 3rd visit was non-significant (P > 0.05). The
progressive reduction (from 1st to 3rd visit) observed in
absolute lymphocyte and total WBC may indicate sup-
pressive activity of the antiretroviral drug on the virus
with the resultant increase in leucopenia (mild leuco-
penia; 26.8% to 30%) and lymphocytopenia (moderate
lymphocytopenia; 1% to 10%). Leucopenia (a decrease in
the number of white blood cells ) and Lymphopenia (de-
crease in lymphocyts) are the hallmarks of HIV infection
and is thought to be mediated by infection of the virus
with subsequent killing of CD4+ T cells. It can also be
caused by certain medications such as ART [35-37] and
certain infections [38,39]. The significant reduction
found in the lymphocyte count at the 2nd visit follows
the pattern already reported by Stein and his colleagues
[40]. However, the transient lymphopenia is common
and one-third of the patients may have a typical lympho-
cytes in the peripheral blood smear. The mechanism re-
sponsible for leucopenia and lymphopenia could be an
accumulation of Winniecure metabolites (though not
determined empirically). We would not de-emphasize
the possibility of a pseudoleucopenia since the result
showed a mild leucopenia and an increase in Hb as the
treatment progresses. Further investigation is needed to
ascertain this since the study is devoid of CD4 and viral
load assessments hence its limitation.
Several research works have shown that administration
of ART especially Zidovudine (AZT) therapy causes an-
aemia with a significant reduction in Hb in HIV patients
[41] even at 6 weeks of administration [42,43]. Interest-
ingly, the result showed an increased PCV at the 2nd and
3rd visits, the data tend to have similar progression with
the values obtained from Hb. This suggests an effective
therapeutic effect of the drug at the 12th week/3rd visit
since a decreased PCV indicates anaemia. The increase
at the 3rd visit may indicate a peak active period of the
Winniecure treatment within the observation time frame
with the resultant reduction of anaemia from 76% to
31%. Recent research works have also shown that mean
haemoglobin increases significantly in patients who re-
ceive ART thus reversing HIV associated anaemia [44].
The consistent reduction of ESR (41.46 ± 31 to 32.12 ±15.49) and eosinophil (197.01 ± 1.42 to 132 ± 1.42) from
1st week to 12th week attest to the reduced anaemic con-
dition found in the HIV subjects on Winniecure therapy.
Raised ESR and esonophil levels have also been shown
to indicate acute anaemic condition [45]. ESR increased
significantly when compared with the control, this often
may rise significantly in individuals due to infection or
medication and merely reflect the anaemic condition
seen in these subjects. Moreso, Ndakotsu et al. [46] have
reported high ESR in HIV patients of Nigerian origin.
A significant reduction in both differential and abso-
lute granulocyte count was observed between the 1st and
3rd visits. Using the National Cancer Institute-Common
Toxicity Criteria (NCI-CTC) Version 2.0 it was found
that the subjects undergoing treatment are at NCI risk
category 1, implying a mild neutropenia. It is of note
that abnormal granulopoiesis and anti-granulocyte anti-
bodies have been noted and described in 30-70% of HIV
infected patients [47]. This is believed to contribute to
the observed increase in neutropenia (4.2 to 8%). The
major clinical significance of the HIV induced neutro-
penia is that it often precludes therapy with ART and
some drugs used for the treatment of opportunistic dis-
eases [48]. The low granulocyte count seen in the 3rd
visit may reflect the action of Winniecure on HIV infec-
tion or associated conditions. The incidence of neutro-
penia at the first visit (untreated patients) is consistent
with other reports [49] which have also shown a high in-
cidence of granulocytopenia particularly in patients with
more profound immunodeficiency.
An escalated and uncontrolled platelet count may indi-
cate disease progression and may sometimes be associated
with abnormal bleeding. Thrombocytopenia however, is
defined as any disorder in which there is an abnormally
low amount of platelets which may result due to immune
system malfunction [50]. The result here showed a con-
sistent and significant increase in platelet count from
the 1st to the 3rd visits. This indicates a reduced inci-
dence of thrombocytopenia in the HIV+ ART subjects.
This action maybe adduced to the activity of the admin-
istered Winniecure.
Numerous studies have found that liver problems are
the most common non-AIDS cause of death among
people with HIV infection. Also liver-related death is
one of the major causes of mortality accounting for 14-
18% of all deaths in the effective antiretroviral therapy
era [51-53]. The findings show an elevated liver trans-
aminase enzymes (AST: 34.311 U/L, ALT: 38.47 U/L and
ALP: 97.31 U/L) from baseline (1st visit) to the 12 th
week (3rd visit). It is of note that this increase is still within
the normal laboratory reference ranges and the result
however agrees with the report of Abdullahi et al. [24].
It is our opinion that long term administration of the
drug should be guarded to avoid possible drug induced
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mens studied, the greatest risk of developing drug in-
duced liver injury has been observed among patients
on long term therapy receiving full-dose of ritonavir
with elevated hepatic enzymes. Furthermore, birirubin
a green tetrapyrrolic bile pigment is created by the ac-
tivity of biliverdin reductase on biliverdin as a product
of haeme catabolism. It is also cleared by the liver. The
increased direct bilirubin value obtained shows normal
conjugation of bilirubin by the liver. Similarly, albumin
a protein made specifically by the liver, is slightly de-
creased (3.02 ± 2.8 U/I) at the 12th week thus indicating
a non-significant change.
The pancreatic enzyme amylase (71.21 ± 41.26 U/I)
was mildly elevated at the 12th week/3rd visit. Though
amylase increased during treatment, it is still within the
normal reference range. No case of hyperamylasaemia
could be established at the 12th week of administration
but there could be possibility of elevated levels at long
term treatment. Similarly, plasma creatinine and urea an
excellent indicator of kidney function did not show any
significant change in their plasma levels between 1st and
3rd visits and with the reference values. This may indi-
cate a normal functional and intact kidney.
In summary the efficacy of the drug has a reduced
haematological and biochemical abnormalities with a nor-
mal kidney function. The drug seems to may have worked
optimally at about 12 weeks of treatment within the
period of test thereby indicating appreciative positive
changes in the haematological and biochemical indices
measured. These results show that the therapeutic efficacy
measured on haematological and biochemical responses
are accompanied by a reduction of these (parameters mea-
sured) indicators of abnormality. They also suggest pos-
sible tendency of the administered ART to drive a shift
from the physiological normal ranges of haematological
and biochemical (mostly liver damage) indices of healthy
status to an elevated range.
Admittedly, the study did not consider the intriguing
possibility of symptomatic improvement, palliative bene-
fit and CD4 count improvement of the administered
drug nor its comparison with any other known anti-
retroviral drugs thus its limitation.
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